Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AZD 3759

Drug Profile

AZD 3759

Alternative Names: AZD-3759; EGFR antagonist - AstraZeneca; Epidermal growth factor receptor tyrosine kinase inhibitor - AstraZeneca

Latest Information Update: 13 Dec 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Developer Alpha Biopharma; AstraZeneca
  • Class Amines; Antineoplastics; Piperazines; Quinazolines
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Non-small cell lung cancer

Most Recent Events

  • 29 Oct 2018 Phase-II/III clinical trials in Non-small cell lung cancer (First-line therapy, Late-stage disease) in Singapore, South Korea, China (PO) (NCT03653546)
  • 31 Aug 2018 Alpha BioPharma plans a phase II/III trial for Non-small cell lung cancer (First-line therapy, Late-stage disease, Metastatic disease) in China, Singapore and Taiwan (NCT03653546)
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top